Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables
NCT07533084, Not yet recruiting, Neuromed IRCCS
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables | ClinicalTrials.gov |
| NCT number | NCT07533084 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Enrollment | 265 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Neuromed IRCCS | ClinicalTrials.gov |
| Conditions | Active Aging Individuals Aged 65 and Over, Aging, Mild Cognitive Impairment (MCI), Dementia, Dementia Alzheimer Type, Subjective Memory Complaints, Probable Alzheimer's Disease | ClinicalTrials.gov |
| First posted | 2026-04-16 | ClinicalTrials.gov |
| Last updated | 2026-06-11 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Italian Validation and Factor Structure of the dynamic Neurocognitive Adaptation Scale (dNA) | From enrollment until the completion of dNA scale administration at the time of enrollment. | The primary outcome of this study is the successful Italian validation of the dNA scale. Specifically, investigators expect to replicate the results of the English-language version (Cieri et al., accepted), with a four-factor structure, no multicollinearity (r \< 0.95) or insufficient common variance (r \< 0.3), satisfactory Kaiser-Meyer-Olkin (KMO) indices (\>0.70), significant Bartlett's sphericity test (\<0.01), and high internal consistency as indicated by Cronbach's alpha (\>0.80). | ClinicalTrials.gov |
| Secondary | Association Between Activity Engagement, Temporal Maintenance, and Educational Attainment | From enrollment until the completion of dNA scale administration and demographic assessment at the time of enrollment. | Investigators expect that greater engagement in the activities under investigation, as well as their dynamic maintenance over time, reflected in higher dNA scale scores, will be positively associated with higher educational attainment. | ClinicalTrials.gov |
| Secondary | Association Between dNA scale and Neuropsychological Measures | From enrollment until the completion of dNA scale administration and the neuropsychological assessment. | Investigators expect that higher dNA scale scores will be positively associated with better neuropsychological performance, particularly in episodic memory and executive function domains. Specifically, cognitive performance will be assessed using a standardized battery, including the MMSE (or MoCA) for global cognition, Rey Auditory Verbal Learning Test (RAVLT) for verbal long-term memory, Trial Making Test (TMT) Form B for executive functioning, Digits Forward and Backward subtests (WAIS or WAIS-III) for working memory, Wechsler Memory Scale Logical Memory II (or Prose Memory), and Stroop Test for cognitive inhibition and information processing speed. These measures will provide both an overall cognitive assessment and domain-specific outcomes, which will be further explored for their expected association with the dNA scale scores. | ClinicalTrials.gov |
| Secondary | Association Between dNA scale and Structural and Functional Brain Organization | From enrollment until the completion of dNA scale administration and the neuroimaging acquisition. Structural MRI and functional MRI will be conducted at baseline if not already available from the participant registry. | This outcome measure evaluates the relationship between dNA scale scores and functional brain network activity and organization derived from functional magnetic resonance imaging (fMRI). Within diagnostic groups (SMC, MCI, AD), higher scores on the dNA scale are hypothesized to be associated with increased activation and greater functional segregation within the task-negative network (default network, DN), alongside greater deactivation in task-positive networks, including the dorsal attention network (DAN) and the frontoparietal control network (FPCN). Functional connectivity analyses will be used to quantify both within-network segregation and between-network integration. These neuroimaging-derived metrics will be statistically associated with dNA scale scores using appropriate regression models within each diagnostic group. | ClinicalTrials.gov |
| Other | Association Between dNA scale and Biomarkers of Pathological Aging | From enrollment until the completion of dNA scale administration and retrieval of relevant information from the participant's medical record. | This additional outcome measure will evaluate the relationship between dNA scale scores and previously collected biomarkers, contingent upon data availability. Indeed, participating centers that have the capability may also retrieve information from the participant's medical record regarding biomarkers of pathological aging (e.g., APoE). Potential association between dNA scale scores and previously collected biomarkers will be further explored, within the healthy elderly sample and each diagnostic group (SMC, MCI, AD). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 4
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Short Story Recall | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)